查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
猴痘治疗的全球市场:市场规模 - 各治疗，各产品类型，各剂型，各给药途径，各年龄，性别，各处方类型，各终端用户，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1208370

猴痘治疗的全球市场:市场规模 - 各治疗，各产品类型，各剂型，各给药途径，各年龄，性别，各处方类型，各终端用户，各地区展望，竞争策略，各市场区隔预测(～2032年)

Monkeypox Treatment Market Size- By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 248 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球猴痘治疗的市场规模，预计至2032年达到2亿3,000万美元，以10.37％的年复合成长率成长。全球猴痘病例增加，是促进市场收益成长的主要原因。

本报告提供全球猴痘治疗市场相关调查，市场动态，市场变数与展望，各治疗、产品类型、剂型、给药途径、年龄、性、处方类型、终端用户、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球猴痘治疗市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 竞争情形

  • 全球猴痘治疗的製造地流通，销售区域，产品类型
  • 全球猴痘治疗市场的合併、收购，伙伴关係，产品的销售，合作

第7章 全球猴痘治疗市场:各治疗(2019年～2032年(100万美元))

  • 药物疗法
    • 止痛药
    • 停镇护者痒剂、痒
    • 解热止痛药
    • 抗病毒药物
  • 疫苗
    • 天花疫苗
    • JYNNEOS/Imvanex
  • 牛痘免疫球蛋白(VIG)

第8章 全球猴痘治疗市场:各产品类型(2019年～2032年(100万美元))

  • 乳霜
  • 凝胶
  • 注射剂
  • 软膏
  • 锭剂

第9章 全球猴痘治疗市场:各剂型(2019年～2032年(100万美元))

  • 液体
  • 半固体
  • 固体

第10章 全球猴痘治疗市场:各给药途径(2019年～2032年(100万美元))

  • 口服
  • 非口服
  • 局部

第11章 全球猴痘治疗市场:各年龄(2019年～2032年(100万美元))

  • 成人
  • 老人
  • 儿童

第12章 全球猴痘治疗市场:性别(2019年～2032年(100万美元))

  • 女性
  • 男性
  • 其他

第13章 全球猴痘治疗市场:各处方类型(2019年～2032年(100万美元))

  • OTC(一般用医药品)
  • Rx(处方笺医药品)

第14章 全球猴痘治疗市场:各终端用户(2019年～2032年(100万美元))

  • 医院药局
  • 线上药局
  • 零售药局

第15章 全球猴痘治疗市场:各地区(2019年～2032年(100万美元))

  • 全球猴痘治疗的规模、市场占有率:各地区(2019年～2025年)
  • 全球猴痘治疗的规模、市场占有率:各地区(2026年～2032年)
  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的亚太地区
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的欧洲
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲
  • 北美
    • 加拿大
    • 墨西哥
    • 美国
  • 南美
    • 阿根廷
    • 巴西
    • 其他的南美

第16章 企业简介

  • Bavarian Nordic
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Chimerix
  • CIDIC Co., Ltd.
  • EMERGENT
  • Hetero
  • Olon S.p.A
  • Piramal Pharma Solutions
  • SIGA Technologies
  • Teva Pharmaceutical Industries Ltd.

第17章 简称一览

第18章 参照链接

第19章 结论

第20章 调查范围

简介目录
Product Code: HLCA2303

Global Monkeypox Treatment Market Overview

According to SPER Market Research, the Global Monkeypox Treatment Market is estimated to reach USD 0.23 billion by 2032 with a CAGR of 10.37%.

The monkeypox virus is the source of this uncommon but severe illness. Since monkey pox is a contagious disease, it can be spread by sick people, animals, or even contaminated objects. The monkeypox virus results in skin lesions and rashes on every part of the diseased body. Monkeypox symptoms and signs include fever, swollen lymph nodes, aches and chills, and muscle pain.

The market for monkeypox is anticipated to grow quickly in terms of CAGR. The increase in monkeypox cases worldwide is the main factor driving monkeypox market revenue growth.One of the main factors propelling the growth of the monkeypox market is the increase in monkeypox prevalence as a result of the rise in viral infections brought on by the monkeypox virus. The monkeypox virus can cause viral infection in people with weakened immune systems. Increase in numerous chronic illnesses and dermatological conditions like eczema, which causes weakened immunity and increases the risk of contracting the monkeypox virus, leads to the expansion of the monkeypox market.The market expansion of monkeypox treatments is supported by increased research and development for the treatment of monkeypox as well as rising global demand for the therapy.

Impact of COVID-19 on the Global Monkeypox Treatment Market

The recent COVID-19 pandemic has resulted in weakened immunity in those affected, which raises the risk of monkeypox virus infection. Monkeypox market expansion was boosted by a large population that was infected with COVID-19. Businesses across all industries are struggling financially as a result of the global lockdown caused by the corona virus (COVID-19) epidemic. Global supply chains and manufacturing operations have been affected as a result of lockdowns imposed by national authorities, travel restrictions, and other COVID-19 safety measures. However, the market for treating monkeypox is barely impacted by COVID-19.However, due to a significant lack of medical supplies and raw materials, manufacturing locations located in the worst-hit nations have been badly impacted. This has disrupted the world's supply chains.The Food and Drug Administration (FDA) of the United States is still keeping tabs on the supply chain. In order to improve the supply chain of medical products in the future, the Center for Drug Evaluation and Research (CDER) Drug Shortage Staff asked manufacturers to assess their entire supply chain of various products, including ethanol, EDTA (Ethylenediaminetetraacetic acid), and vaccine manufacturing equipment, among others.

Scope of the Report:

Report Metric Details

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User
  • Regions covered: Asia Pacific, Europe, Middle East and Africa, North America, Latin America
  • Companies Covered: Bavarian Nordic, Chimerix, CIDIC Co., Ltd., EMERGENT, Hetero, Olon S.p.A, Piramal Pharma Solutions, SIGA Technologies, Teva Pharmaceutical Industries Ltd.

Global Monkeypox Treatment Market Segmentation:

  • By Treatment: Based on the Treatment, Global Monkeypox Treatment Market is segmented as; Medications (Analgesics, Antipruritic or Anti-itch drugs, Antipyretics, Antivirals), Vaccine (Smallpox Vaccine, JYNNEOS/Imvanex), Vaccinia Immune Globulin (VIG).
  • By Product Type: Based on the Product Type, Global Monkeypox Treatment Market is segmented as; Creams, Gels, Injectable, Ointment, Tablets.
  • By Dosage Form: Based on the Dosage Form, Global Monkeypox Treatment Market is segmented as; Liquid, Semi Solid, Solid.
  • By Prescription Type: Based on the Prescription Type, Global Monkeypox Treatment Market is segmented as; Over the counter (OTC) drugs, Prescription (Rx) drugs.
  • By End User: Based on the End User, Global Monkeypox Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • By Region: Over the forecast period, the monkeypox market in Asia Pacific is anticipated to develop at the quickest rate. Other factors contributing to the market expansion in the region include an increase in the number of patients with monkeypox, government activities to raise public awareness, and an increase in demand for the treatment.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Monkeypox Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Monkeypox Treatment Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Monkeypox Treatment Market

7. Global Monkeypox Treatment Market, By Treatment, 2019-2032 (USD Million)

  • 7.1 Medications
    • 7.1.1 Analgesics
    • 7.1.2 Antipruritic or Anti-itch drugs
    • 7.1.3 Antipyretics
    • 7.1.4 Antivirals
  • 7.2 Vaccine
    • 7.2.1 Smallpox Vaccine
    • 7.2.2 JYNNEOS/Imvanex
  • 7.3 Vaccinia Immune Globulin (VIG)

8. Global Monkeypox Treatment Market, By Product Type, 2019-2032 (USD Million)

  • 8.1 Creams
  • 8.2 Gels
  • 8.3 Injectable
  • 8.4 Ointment
  • 8.5 Tablets

9. Global Monkeypox Treatment Market, By Dosage Form, 2019-2032 (USD Million)

  • 9.1 Liquid
  • 9.2 Semi Solid
  • 9.3 Solid

10. Global Monkeypox Treatment Market, By Route of Administration, 2019-2032 (USD Million)

  • 10.1 Oral
  • 10.2 Parenteral
  • 10.3 Topical

11. Global Monkeypox Treatment Market, By Age, 2019-2032 (USD Million)

  • 11.1 Adults
  • 11.2 Geriatrics
  • 11.3 Paediatrics

12. Global Monkeypox Treatment Market, By Gender, 2019-2032 (USD Million)

  • 12.1 Female
  • 12.2 Male
  • 12.3 Others

13. Global Monkeypox Treatment Market, By Prescription Type, 2019-2032 (USD Million)

  • 13.1 Over the counter (OTC) drugs
  • 13.2 Prescription (Rx) drugs

14. Global Monkeypox Treatment Market, By End User, 2019-2032 (USD Million)

  • 14.1 Hospital Pharmacy
  • 14.2 Online Pharmacy
  • 14.3 Retail Pharmacy

15. Global Monkeypox Treatment Market, By Region, 2019-2032 (USD Million)

  • 15.1 Global Monkeypox TreatmentSize and Market Share by Region (2019-2025)
  • 15.2 Global Monkeypox TreatmentSize and Market Share by Region (2026-2032)
  • 15.3 Asia-Pacific
    • 15.3.1 Australia
    • 15.3.2 China
    • 15.3.3 India
    • 15.3.4 Japan
    • 15.3.5 South Korea
    • 15.3.6 Rest of Asia-Pacific
  • 15.4 Europe
    • 15.4.1 France
    • 15.4.2 Germany
    • 15.4.3 Italy
    • 15.4.4 Spain
    • 15.4.5 United Kingdom
    • 15.4.6 Rest of Europe
  • 15.5 Middle East & Africa
    • 15.5.1 Kingdom of Saudi Arabia
    • 15.5.2 United Arab Emirates
    • 15.5.3 Rest of Middle East & Africa
  • 15.6 North America
    • 15.6.1 Canada
    • 15.6.2 Mexico
    • 15.6.3 United States
  • 15.7 Latin America
    • 15.7.1 Argentina
    • 15.7.2 Brazil
    • 15.7.3 Rest of Latin America

16. Company Profiles

  • 16.1 Bavarian Nordic
    • 16.1.1 Company details
    • 16.1.2 Financial outlook
    • 16.1.3 Product summary
    • 16.1.4 Recent developments
  • 16.2 Chimerix
    • 16.2.1 Company details
    • 16.2.2 Financial outlook
    • 16.2.3 Product summary
    • 16.2.4 Recent developments
  • 16.3 CIDIC Co., Ltd.
    • 16.3.1 Company details
    • 16.3.2 Financial outlook
    • 16.3.3 Product summary
    • 16.3.4 Recent developments
  • 16.4 EMERGENT
    • 16.4.1 Company details
    • 16.4.2 Financial outlook
    • 16.4.3 Product summary
    • 16.4.4 Recent developments
  • 16.5 Hetero
    • 16.5.1 Company details
    • 16.5.2 Financial outlook
    • 16.5.3 Product summary
    • 16.5.4 Recent developments
  • 16.6 Olon S.p.A
    • 16.6.1 Company details
    • 16.6.2 Financial outlook
    • 16.6.3 Product summary
    • 16.6.4 Recent developments
  • 16.7 Piramal Pharma Solutions
    • 16.7.1 Company details
    • 16.7.2 Financial outlook
    • 16.7.3 Product summary
    • 16.7.4 Recent developments
  • 16.8 SIGA Technologies
    • 16.8.1 Company details
    • 16.8.2 Financial outlook
    • 16.8.3 Product summary
    • 16.8.4 Recent developments
  • 16.9 Teva Pharmaceutical Industries Ltd.
    • 16.9.1 Company details
    • 16.9.2 Financial outlook
    • 16.9.3 Product summary
    • 16.9.4 Recent developments

17. List of Abbreviations

18. Reference Links

19. Conclusion

20. Research Scope